Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.77 |
| ▸ | IKBKB | O14920 | 7/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | ROS1 | P08922 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | FGR | P09769 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16331617 | 0.89 | FYN (0.78) | FYNIKBKBMAPK10NTRK1NTRK3 | |
| SCHEMBL1055387 | 0.88 | FYN (0.82) | FYNIKBKBMAPK10PIM1NTRK1 | |
| SCHEMBL30521746 | 0.87 | FYN (1.00) | FYNIKBKBMAPK10PIM1 | |
| SCHEMBL2941291 | 0.87 | FYN (1.00) | FYNIKBKBMAPK10PIM1 | |
| SCHEMBL2948971 | 0.87 | FYN (0.84) | FYNIKBKBMAPK10PIM1NTRK1 | |
| SCHEMBL30521811 | 0.87 | FYN (1.00) | FYNIKBKBMAPK10PIM1NTRK1 | |
| SCHEMBL18613504 | 0.87 | FYN (1.00) | FYNIKBKBMAPK10PIM1NTRK1 | |
| SCHEMBL2943785 | 0.85 | FYN (0.79) | FYNIKBKBMAPK10NTRK1NTRK3 | |
| SCHEMBL2951009 | 0.84 | FYN (0.74) | FYNIKBKBMAPK10PIM1NTRK1 | |
| SCHEMBL18613351 | 0.84 | FYN (1.00) | FYNIKBKBMAPK10PIM1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | FYN 574/4885IKBKB 525/4885MAPK10 438/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | FYN 421/4885IKBKB 207/4885MAPK10 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.